Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib

  • Donald Harvey
  • Clinical Pharmacology Advances and Applications, May 2014, Taylor & Francis
  • DOI: 10.2147/cpaa.s62512

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.2147/cpaa.s62512